Name | S-Ruxolitinib |
---|---|
Synonyms |
1H-Pyrazole-1-propanenitrile, β-cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, (βS)-
ent-Ruxolitinib (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile Ruxolitinib (S enantiomer) (3S)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile (S)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile INCB018424 |
Description | Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays. |
---|---|
Related Catalog |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 592.6±50.0 °C at 760 mmHg |
Molecular Formula | C17H18N6 |
Molecular Weight | 306.365 |
Flash Point | 312.2±30.1 °C |
Exact Mass | 306.159302 |
PSA | 83.18000 |
LogP | 1.69 |
Vapour Pressure | 0.0±1.7 mmHg at 25°C |
Index of Refraction | 1.747 |
Storage condition | -20℃ |